



REAL-WORLD IMPLEMENTATION OF RECENT
TG REPORTS

TG-263: STANDARDIZING NOMENCLATURES IN RADIATION ONCOLOGY

Courtney R Buckey, PhD, DABR
Mayo Clinic Arizona

AAPM VIRTUAL SPRING CLINICAL MEETING
APRIL 17-20, 2021
Parent Session: From Page to Clinic - Bringing Good Ideas to Your
Physics Group



LEARNING OBJECTIVES

- At the conclusion of this talk attendees will...

1

Understand the rationale for implementing standardized nomenclature in their clinic, department or group

2

Be familiar with the guidelines and recommendations found in TG-263

3

Feel more comfortable with beginning a new nomenclature initiative, including how to motivate others and how to keep oneself on track



DISCLOSURES

I have no relevant financial interests to disclose related to this talk or this work

Some of the tools discussed in this presentation may be adapted for commercial applications in the future

I am a brand-new member of TG-263U1, but was not involved in the original report



NOMENCLATURE: WHAT'S IN A NAME?

From personal identity to brand recognition, and from classic literature to modern science (and even science fiction!), names have an impact in how we perceive and interact with the world

BENEFITS OF STANDARDIZATION

Broadly speaking, standardization drives decreases in variation, stress, and training time; increases in quality and reliability; and forms a baseline for continuous improvement



CHARGE STATEMENT

To provide nomenclature guidelines in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing:

Standardizing Nomenclatures in Radiation Oncology

The Report of AAPM
Task Group 263

January 2018



CHARGE 1

structure names across image processing and treatment planning system platforms



CHARGE 2

nomenclature for dosimetric data (e.g., dose/volume histogram [DVH]-based metrics)



CHARGE 3

templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards



CHARGE 4

formalism for nomenclature schema which can accommodate the addition of other structures defined in the future



TOWARDS SAFER PATIENT CARE

- “Common nomenclature increases safety by minimizing variability and ambiguity”
- Standardized rules permit automated solutions to check nomenclature itself, and trigger evaluations of plan quality metrics that are driven by the consistent application of names and conventions
 - Targets
 - Laterality
 - Planning approaches




WHAT IS OUR GOAL?

“The difference between a safe practice and special practice”



POSITIVE INFLUENCES


Improved communication in radiation therapy is a cornerstone of ASTRO's white paper on standardizing dose prescriptions



CHALLENGES

DESPITE SOME PROGRESS

- Vendor-based challenges
 - Inter-vendor variation on constraints for character strings used for structures, including length, special characters, and capitalization
- Multi-institutional-based challenges
 - Lack of a clear multi-institutional oversight group to take charge of coordinating the standards
 - Lack of guidelines that extend across multiple languages, even when the specific names cannot
 - Challenges with mapping previously utilized nomenclature to new standards
- Single institutional-based challenges
 - Cost and effort to implement a new nomenclature
 - Consistent use of standards by the range of staffing groups interacting with patient charts (e.g., physicians, physicists, therapists, and dosimetrists)
- Clinical staff challenges
 - Inconsistent approaches to consider/define laterality and other structure qualifiers
 - Lack of detailed and site-specific guidelines for the definition of target structures to enable automated computer algorithms to extract relevant information
 - Lack of clear guidelines for clarifying or incorporating new elements of a standard nomenclature



NEED HELP JUSTIFYING THIS TO YOUR TEAM?

- Standardized nomenclature:
 - enhances safety and quality efforts within and between clinics for routine ongoing practice
 - enables data pooling for outcomes research, registries, and clinical trials
 - is a vital precursor to the development of scalable uses of scripting for quality assurance and treatment plan evaluation


NEED HELP GETTING THE WORK STARTED?

- TG-263's Section 13 has an implementation plan and good advice
 - “Even a basic effort to change to standardized structure naming is beneficial for the individual clinic, as well as the radiation oncology community as a whole”
 - The authors recommend gradual implementation, to allow time to build familiarity
- 1 Identify common treatment sites and corresponding staffing groups affected by changes in nomenclature
 - 2 Detail commonalities already in use for those treatment sites
 - 3 Discuss the final list, and guidelines with the disease site groups and other stakeholders in your clinic as required by your organizational structure
 - 4 Identify local documentation templates used in the clinical practice that may need to be adjusted along with changes to the nomenclature
 - 5 Develop a plan for gradual rollout of the nomenclature into clinical practice
 - 6 Develop a short list and create templates in your treatment planning system containing your new standard structures



RECOMMENDATIONS

- Physicians, dosimetrists, physicists and therapists would all like to convey the maximum amount of information
 - There are meaningful limitations within the software that we use (image acquisition, treatment planning, record and verify, quality assurance...)
 - With that in mind, the authors of TG-263 aimed to develop a nomenclature system that could
 - be widely adopted in the vended systems as they currently exist and
 - permit new definitions of data element representations for encapsulating a fuller representation of the data
-
- *Defined structure is human-readable*
 - *Sufficient information avoids ambiguity between similar items in the system*



**NON-TARGET
STRUCTURE
NOMENCLATURE**



**TARGET STRUCTURE
NOMENCLATURE**




**DOSE VOLUME
HISTOGRAM METRICS**



**DISTINGUISHING METRICS
OF SEGMENTED VS NON-
SEGMENTED TARGET
STRUCTURES**




VENDORS



COLOR SPECIFICATION





THE MAYO ARIZONA EXPERIENCE



14 PHYSICIANS
4 RESIDENTS



16 DOSIMETRISTS



18 PHYSICISTS
4 RESIDENTS



48 THERAPISTS



4 LINACS
4 PROTON GANTRIES



2 CT SIMULATORS
1 IORT
1 HDR

How frustrations lead to change

- [illegible]

How key staff have joined the department, from 1985 through 2020

RX STANDARDIZATION CAME FIRST

- Our very first steps, in 2018:
 - Initiated a standardization effort
 - Canvassed opinions, but kept decision making to a small group
 - Kept Rx simple and predictable
 - Got buy-in from key stakeholders and then hit the campaign trail
- This was spearheaded by one of our newer radiation oncologists, Dr. Thomas Daniels
- His enthusiasm and gusto had a tremendously positive effect on this initiative
- His subsequent ascension to a leadership role in the clinical practice of the department gave weight to his projects



Dr. Daniels is now service chief of the Department of Radiation Oncology at Perlmutter Cancer Center–Sunset Park



WITH THE RX SUCCESS, WE BROADENED THE HORIZONS

- We decided to aim for a complete overhaul of our internal nomenclature
 - Course ID
 - Plan ID
 - Target ID
 - Rx Name
 - Reference Point ID
- Formed a *very* small group: one physician, two physicists
 - Held many *many* meetings
 - Used many *many* whiteboard markers
- Carefully reviewed TG-263
- Looked back at the wide variety of names and identifiers that had been used previously
- Thought about our technological limitations (Aria/Eclipse, Epic, Varian TrueBeam, Hitachi)

- Single institutional-based challenges
 - Cost and effort to implement a new nomenclature
 - Consistent use of standards by the range of staffing groups interacting with patient charts (e.g., physicians, physicists, therapists, and dosimetrists)
- Clinical staff challenges
 - Inconsistent approaches to consider/define laterality and other structure qualifiers
 - Lack of detailed and site-specific guidelines for the definition of target structures to enable automated computer algorithms to extract relevant information
 - Lack of clear guidelines for clarifying or incorporating new elements of a standard nomenclature



RT BRST BST:1	LUL NEW	TBI CTB Adult	Prost Fossa	HN_replan	T10_L3	Abdomen	L Breast	Lt Femur	
Rt Breast	SRS Cone 5A4T	L1_3	R Cheek	Whole Brain	Abdomen	PreSacralNode	Pelvis	Lt Axilla	R_pelvis
R_breast	SRSV5A4T RCer	R Lung SBRT	LLung SBRT	C7_T6	Oral Cavity	T1_T4Spn	SRS V 5A4T	L Humerus	R_scar boost
RT BRST TOTAL	Rectum_boost	Sternum	pancreas retx	Bilat Ribs	SRS V 5A4T	WholeBrain	Pelvis Boost	R Humerus	HN
LT BRST TOTAL	Rectum	T9	LUL	SRS V 5A4T	R Humerus_FiF	LtFemur	Lt Breast	T8_11	RtCWSCV
SRS	Pros Bed	WholeBrain	Vagina	scalp	R Parotid	Tspine	LBRST	nasal 6e_9e	AbdomenRABst
LRec	boost pelvis	LtBreast_FiF	Rt Flank		boost		PA node	BOT_necksRP	AbdomenRA
T5_T							LS SPINE	ProstateBed	Lt Breast Bst
L_Lia							RtScapula	SRS V 5A4T	Left Breast
RtFe							SRS Pituitary	Prostate SBRT	T7_T9 1fx
L Hip							CT SPINE	LT Sacrum_C3	Lt Hip 1fx
RP1							Prost SBRT	T4-T9 V3:1	L3_L4 1fx
L Lung							RtCW	R_upper_lip	L_cheek
L Bronchus	Pancreas	Rt Ribs	Scar Bst R CW	SRT V 5A4T	Lt Neck	SRS V 5A4T	RUL	RT SHLDR	Brain
NODES	R Lung	Lt Ribs	SRS V 5A4T	Rt Shoulder	Eso_T5_T9_FiF	head_neck	TBI	WholeBrain	
Abdomen	Prostate_SV	LtKnee	SRS 4 Mets	Sacrum_FiF	SRT Mening				
SRS RtPariet	RtLung	Lt Breast	Rt Lung	WBRT_FiF	H_N				
PROST FOSSA	SRS2 R pariet	Prostate	prost_sv	pelvis	SRT V 5A4				
SRS LtFrontal	SRS1 R front		L_lung hybrid	LtLung	L H_N_C1				
SRS PTV01 LCC	Pelvis_PA	Forehead	SRS LtParagan	T5_L2	Abdomen				
SRS PTV02 ROL	Pros Bed	T2_T8_FiF	TBI CTB Adult	Left Breast	PreSacralN				
SRS RtPariet	celiac node	R_foot	L Breast Bst	WholeBrain	T1_T4Spn				
SRS LtPariet	Prostate_SV	Prostate1	TSpineSBRT	HN	WholeBrain				
LtHumerus	RtThigh	LT FLANK	Lt Thigh	Mesenteric	LtFemur				
RUL Lung	LtHip	C5_T1	RT BRST	Prost Bed	Tspine				
THYROID	RtHip	Sternal CW	LBRST_SCV_FiF	Mediastinum	HN				
replan 2_18fx	TBI CTB Adult	Lt Breast	RtLung	LLL SBRT	LtChest				
RtTibia_FiF	L1_3	BreastBoost	L1_5 Spine	ProstateBed	Lt Clavicle				
Rfemur_AP_FiF	R Lung SBRT	RBreast_Sclv_	L Breast Bst	T10_L3	T5_L1				
Rfemur_PA_FiF	Sternum	Pelvis_Prost	Prostate_SV	Abdomen	L_oral cavi				
RT HIP	T9	HN	RT HIP	Oral Cavity	Sternum				
SRS R Occ Cav	WholeBrain	RLL SBRT	Brain_FiF	SRS V 5A4T	Rt Hip				
	LtBreast_FiF	LtBreastBoost	T5_T8 Spine	R Humerus_FiF	SRS V 5A4				
	PelvisSBRT	RUL Lung	LT BRST	R Parotid	head_neck				
	SRS Cone L Fr	PROST BED	L2 Sacrum	boost	Nose				
	RIGHT LUNG	Pros Bed	Whole Brain	pelvis	LtAdrenal				
		Pleural mass			upper ches				

hippo sparing



WORKING WITHIN THE CONFINES OF OUR TECHNOLOGY, AND THE HISTORICAL CHARACTERISTICS OF OUR CLINICAL CULTURE WE DEVELOPED A SCHEMA

- All sites will abide by the following ground rules, unless specifically indicated:
 - Course ID (16): **Course** **Number**(2)**AnatomicSites**(9)**MajorTechnique**(4) "MultiSite" is only appropriate within a Course ID
 - Rx Name (16): **AnatomicSites**(9)**Laterality**(1)**Boost**(3)**orMajorTechnique**(4)
 - Plan ID (13): **AnatomicSites**(9)**Laterality**(1)**Boost**(3)**orReplan**(3)
 - Target ID (16): **VolumeDescriptor**(3)**AnatomicSites**(9)**Level**(4)
 - Reference Point ID (16): **DoseLevelincGy**(4)**Modality**(1)**AnatomicSites**(9)**Course**(2)



DECISIONS, DECISIONS



CASE

camelCase

PascalCase



ORDER

OPrimary

ReverseO



ABBREVIATION

We selected 9 characters for anatomic site to severely limit the need for abbreviations



SPATIAL CATEGORIES

We permit these for specific cases:
Extended SSD plans
Plans where ambiguity remains

Making these decisions early allows for faster introduction of new paradigms

But making them too soon might lead to a lot of re-work, be thoughtful and engage stakeholders early and often



AND THEN WE MADE THE BIG LEAP

- The entire system is driven by ICD-10 and anatomy
 - Also drives the insurance approval and reimbursement
 - Limit the number of possible names i.e. for bone mets
 - We have nearly 900 ICD-10 codes with anatomic site names identified and mapped
- Plan names are simple (not a 13 character descriptor of plan nuances)
 - Site, Laterality (when applicable), Boost or Replan
 - Does not include
 - What is being spared, dosimetric facts, elective nodal basins, retreatments
- Goal of 90% predictability
 - Special cases: Peds, CSI, WhBrain, WhAbdomen, TSE, TBI
 - Many 'iconic' radiation fields, particularly for peds, are not going to fit into the strictest confines, but can have unique rules to permit reliability
 - Remained committed to protocol mandates, but will ask for small amounts of duplicate work (eg copying and renaming targets) for data integrity



Codes


- ▶ C34 Malignant neoplasm of bronchus and lung
 - ▶ C34.0 Malignant neoplasm of main bronchus
 - ▶ C34.00 Malignant neoplasm of unspecified main bronchus
 - ▶ C34.01 Malignant neoplasm of right main bronchus
 - ▶ C34.02 Malignant neoplasm of left main bronchus
 - ▶ C34.1 Malignant neoplasm of upper lobe, bronchus or lung
 - ▶ C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung
 - ▶ C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
 - ▶ C34.12 Malignant neoplasm of upper lobe, left bronchus or lung
 - ▶ C34.2 Malignant neoplasm of middle lobe, bronchus or lung
 - ▶ C34.3 Malignant neoplasm of lower lobe, bronchus or lung
 - ▶ C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
 - ▶ C34.31 Malignant neoplasm of lower lobe, right bronchus or lung
 - ▶ C34.32 Malignant neoplasm of lower lobe, left bronchus or lung
 - ▶ C34.8 Malignant neoplasm of overlapping sites of bronchus and lung
 - ▶ C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
 - ▶ C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung
 - ▶ C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
 - ▶ C34.9 Malignant neoplasm of unspecified part of bronchus or lung
 - ▶ C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
 - ▶ C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
 - ▶ C34.92 Malignant neoplasm of unspecified part of left bronchus or lung




THE ROLLOUT PLAN

- Anatomically specific ICD 10
 - GU
 - Lung
 - Brain
 - Head and neck
 - GI
 - Gyn
- Histologically specific ICD 10
 - Lymphoma
 - Sarcoma
 - Bone and Bone mets
 - Skin
- And finally...
 - Breast cancer





**PROSTATE
ROLL OUT**



**ADDITIONAL
SITES**



**GLOBAL
PANDEMIC**



TURNING DIFFICULTIES INTO OPPORTUNITIES

Bone Skin and Misc Nomenclature

[Return to Main Nomenclature Page](#)

Diagnosis Code(s) Covered:

Bone Mets or primary unspecified: "C79.51", "C79.52", "C41.9", "C40.80", "C40.10", "C40.20", "C40.30", "C40.80.0"

Primary Bone of Skull/Face: "C41.0"

Primary Bone of Mandible: "C41.1"

Primary Bone of Spine: "C41.2"

Primary Bone of Thorax: "C41.3"

Primary Bone of Pelvis: "C41.4"

Primary of Rt Arm bones: "C40.01", "C40.11"

Primary of Lt Arm bones: "C40.02", "C40.12"

Primary of Rt Leg bones: "C40.21", "C40.31"

Primary of Lt Leg bones: "C40.22", "C40.32"

Lip Skin: "C44.00", "C44.01", "C44.02", "C44.09", "C43.0", "C44.0"

EyeLid Skin: "C44.101", "C44.111", "C44.121", "C44.131", "C44.101", "C43.10", "C44.10"

Rt EyeLid Skin: "C44.1091", "C44.1091", "C44.1092", "C44.1092", "C44.1191", "C44.1192", "C44.1291", "C44.1291"

Lt EyeLid Skin: "C44.1021", "C44.1021", "C44.1022", "C44.1022", "C44.1121", "C44.1122", "C44.1221", "C44.1222"

Ear Skin: "C44.201", "C44.201", "C44.221", "C44.221", "C43.20", "C44.20"

Rt Ear Skin: "C44.212", "C44.202", "C44.222", "C44.222", "C43.21", "C44.21"

Lt Ear Skin: "C44.219", "C44.209", "C44.229", "C44.229", "C43.22", "C44.22"

Nose Skin: "C44.301", "C44.311", "C44.321", "C44.321", "C43.30", "C44.31"

Face Skin: "C44.300", "C44.309", "C44.310", "C44.320", "C44.300", "C43.30", "C43.39", "C44.30"

Scalp & Neck Skin: "C44.40", "C44.41", "C44.42", "C44.49", "C43.4", "C44.4"

Trunk Skin: "C44.501", "C44.511", "C44.521", "C44.521", "C43.52", "C44.52", "C44.509", "C44.519", "C44.529"

Arm Skin: "C44.601", "C44.611", "C44.621", "C44.621", "C43.60", "C44.60"

Rt Arm Skin: "C44.602", "C44.612", "C44.622", "C44.622", "C43.61", "C44.61"

Lt Arm Skin: "C44.609", "C44.619", "C44.629", "C44.629", "C43.62", "C44.62"

Leg Skin: "C44.701", "C44.711", "C44.721", "C44.721", "C43.70", "C44.70"

Rt Leg Skin: "C44.702", "C44.712", "C44.722", "C44.722", "C43.71", "C44.71"

Lt Leg Skin: "C44.709", "C44.719", "C44.729", "C44.729", "C43.72", "C44.72"

Skin, across multiple sites or not specific: "C44.80", "C44.81", "C44.82", "C44.89", "C44.90", "C44.91", "C44.92", "C44.93"

Treatment Plan QA tool

Plan Review And Nomenclature Kit (P.R.A.N.K.)

Patient Name, MRN: [REDACTED] Machine: FTB

Course: C1MultiSite Plan Status: PlanningApproved

Plan: ICD-10: C79.51 Modality: Linac

Summary Journal Note Contours Exports Nomenclature Unique Nomenclature

Course Anatomy: Spn # plans: 1

Major Technique: Course #: C1

☐ Bone Override

☐ Soft Tissue Override

☐ PCI Override

☐ 2D Override

Add Target

Plan					Volumes				
Anatomy	Bst	Rp	Mode	Relation	#*	Anatomy	Relation	Type	Total Dose (cGy)
Spn			X		1	Spn		Ptv	2000

Spine Details: Start L2 Finish L4

Output: Generate Compare * Number of targets

Current

☒ Plan #1

Course Id: C1MultiSite C1SpnL2L4

Rx Name: SpnL2L4 SpnL2L4

Plan Id: SpnL2L4 SpnL2L4

Ref Pt Ids: 2000XSpnL2L4C1 2000XSpnL2L4C1

Volume Ids: PtvSpnL2-L4 PtvSpnL2L4

Export Results

Treatment Plan QA tool

Plan Review And Nomenclature Kit (P.R.A.N.K.)

Patient Name, MRN: [REDACTED] Machine: FTB

Course: C1MultiSite Plan Status: PlanningApproved

Plan: ICD-10: C79.51 Modality: Linac

Summary Journal Note Contours Exports Nomenclature Unique Nomenclature

Course Anatomy: Spn # plans: 1

Major Technique: Course #: C1

☐ Bone Override

☐ Soft Tissue Override

☐ PCI Override

☐ 2D Override

Add Target

Plan					Volumes				
Anatomy	Bst	Rp	Mode	Relation	#*	Anatomy	Relation	Type	Total Dose (cGy)
Spn			X		1	Spn		Ptv	2000

Spine Details: Start L2 Finish L4

Output: Generate Compare * Number of targets

Current

☒ Plan #1

Course Id: C1MultiSite C1SpnL2L4

Rx Name: SpnL2L4 SpnL2L4

Plan Id: SpnL2L4 SpnL2L4

Ref Pt Ids: 2000XSpnL2L4C1 2000XSpnL2L4C1

Volume Ids: PtvSpnL2-L4 PtvSpnL2L4

Export Results

ALL SITES GAINED SOMETHING



Breast and Lung were reduced from hundreds of plan names, to just a handful

Compliance has been amazing

Always more work to do, some of it with nomenclature, but some of it with modifying physician behavior

Palliative cases with large less “anatomic” volumes remain a challenge

Isolated nodes, nodes as part of a larger volume, and nodes as part of a sequential boost, were our very last challenge, and after much effort, even they have been made to fit the standards



FUTURE WORK

We're hoping physicians will see the usefulness in adding the "met" code to previously treated patients

We'll be doing more robust data analysis as we have more months and years of results


Any change to ICD Codes, will require remapping of our code-to-anatomy correspondence

We continue to refine rules for unusual and nuanced cases, and add in ICD-10s for sites previously unseen in our department

We're working to automate more, and better, which Ed will talk about in his presentation

We eagerly await any updates to TG-263

We didn't attempt any type of non-target nomenclature revisions, that will be a large undertaking, but we have a framework and team in place to help make it a reality at some future time





THANK YOU

A SINCERE THANKS TO THOMAS DANIELS, ED CLOUSER, AND RACHEL GER FOR THEIR WORK ON THIS EFFORT

**HOPING TO TAKE QUESTIONS VIA THE CHAT, OR BY EMAIL AT
BUCKEY.COURTNEY@MAYO.EDU**

HAPPY NOMENCLATURE STANDARDIZING TO ONE AND ALL

